ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1565

Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus

Jagan Sivakumaran1, Paula Harvey 2, Ahmed Omar 3, Murray Urowitz 3, Dafna Gladman 4, Nicole Anderson 3, Jiandong Su 3 and Zahi Touma 3, 1University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: risk assessment and cardiovascular disease, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which cardiovascular risk assessment tool amongst the QRISK2, QRISK3, Framingham (FRS), Modified FRS (mFRS) or SLE Cardiovascular Risk Equation (SLECRE) best predicts CVD in SLE. QRISK3, mFRS and SLECRE are CVD risk assessment tools that consider SLE in risk prognosticating patients.

Methods: Single-centre analyses on prospectively collected data of 1887 SLE patients were performed to compute 10-year CVD risk scores for each tool. Tools’ scores were evaluated against CVD development at or within ten years for cases (CVD events) and controls (no CVD events). For cases, the index date for risk score calculation was chosen 10 years, or as close to 10 years as possible prior to the CVD event. Similarly, for controls, risk scores were calculated as close to 10 years as possible prior to the most recent clinic appointment. Proportions of patients classified as low risk (< 10%), median risk (10-20%) and high risk ( >20%) of developing CVD according to each tool were determined. Sensitivity, specificity, positive/negative predictive values and c-statistics of these tools were analyzed.

Results: 232 total CVD events were seen in the cohort including myocardial infarction, stroke, transient ischemic attack, heart failure and CVD death. QRISK2 and FRS performances were similar, while the QRISK3 and mFRS performances were similar. The SLECRE classified the highest number of patients as median-high risk (Table 1). The sensitivities and specificities are as follows for each tool: QRISK2 (19%, 93%), FRS (22%, 93%), mFRS (46%, 83%), QRISK3 (47%, 78%), SLECRE (61%, 63%), respectively. The tools were similar in negative predictive value, ranging from 89% (QRISK2) to 92% (SLECRE). The FRS and mFRS had the greatest c-statistics, both equaling 0. 73, demonstrating the greatest predictive accuracy amongst the tools, while the QRISK3 and SLECRE had the lowest (0. 67).

Conclusion: While the mFRS performance was superior to the FRS, the QRISK3 did not outperform the mFRS. Although the SLECRE had the highest sensitivity, it had the lowest specificity, demonstrated by grouping the most cases and controls in the median-high risk category. Several factors are important to consider when deciding which risk assessment tools to utilize clinically: ease of use, sensitivity/specificity, and laboratory data accessibility. Thus, the mFRS continues to be a practical tool with a simple, intuitive scoring system appropriate for the ambulatory clinic setting based on the initial weighting of the FRS while adjusting for SLE.

Table 1. Percentage of cases and controls classified as low –<10%-, median -10-20%- and high risk of developing CVD according to each CVD risk assessment tool.


Disclosure: J. Sivakumaran, None; P. Harvey, None; A. Omar, None; M. Urowitz, Janssen Research & Development, LLC, 2, UCB Pharma, 9; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, BMS, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 5, Galapagos NV, 5, Gilead, 5, GSI, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; N. Anderson, None; J. Su, None; Z. Touma, Janssen Research & Development, LLC, 2, Janssen Scientific Affairs, LLC, 2.

To cite this abstract in AMA style:

Sivakumaran J, Harvey P, Omar A, Urowitz M, Gladman D, Anderson N, Su J, Touma Z. Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/assessment-of-the-qrisk2-qrisk3-sle-cardiovascular-risk-equation-framingham-and-modified-framingham-risk-calculators-as-predictors-of-cardiovascular-disease-events-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-qrisk2-qrisk3-sle-cardiovascular-risk-equation-framingham-and-modified-framingham-risk-calculators-as-predictors-of-cardiovascular-disease-events-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology